69467Project Covima: A reclassification application to widen access to a medicine that enables pharmacy to support a major public health need, where services are massively disrupted by C19, with significant societal impactClosedFeasibility StudiesInnovate UK* Helping pharmacists to plug the void in contraceptive services that has resulted as an outcome of the C19 pandemic where access to GP's and sexual health clinics has been severely disrupted with some services suspended altogether. The effect of C19 on the unborn child is currently unknown. * Maxwellia aims to submit a reclassification application to widen access to an oral contraceptive pill to make it available for women to buy in a pharmacy without the need for a doctor's prescription. * This involves: 1. The design of a realistic and deliverable pharmacy supply model 2. Procurement of a suitable marketing authorisation from a contract manufacturer 3. Designing and preparing the key components of the reclassification application for the drug 4. Submitting the application to reclassify the drug to the UK regulator (MHRA) 5. Addressing MHRA concerns to overcome them 6. Managing the process to its successful conclusion. * This will enable more women to access contraceptive services more easily and save money for the NHS by potentially reducing the GP appointments needed to service the 3.3 million prescriptions that are issued for this type of drug each year at an estimated cost of £99m. * Project Covima will help reduce unplanned pregnancy which currently costs the NHS £240m per annum and is set to rise due to C19 where a baby boom (the coronials) is predicted as a result of C19, adding further pressure to the NHS with resultant increased costs for the nation. -Additional information - The extension for impact funding will allow Maxwellia to conduct a study reviewing the success and acceptability of Maxwellia’s first contraceptive product in pharmacy and the effectiveness of the pharmacy training materials to support the MHRA reclassification application.